Shares of Merus N.V. (MRUS) rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its investigational antibody, petosemtamab and Merck’s blockbuster oncology drug Keytruda. This study evaluated the petosemtamab/Keytruda combination as a first-line treatment for patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC). As of the Nov 6, 2023 cut-off date, 26 patients had been tre ...